title: Real-world effectiveness of sitagliptin as add-on therapy in patients with type 2 diabetes mellitus.
abstract: OBJECTIVE
  To assess the effectiveness of sitagliptin in glycemic control in a clinical practice.
  
  
  METHODS
  This was a retrospective medical chart review study conducted in a single hospital. A total of 3081 patients with diabetes mellitus who were prescribed sitagliptin were selected, including 2729 continuous sitagliptin users (defined as continuous usage ≥ 24 weeks) and 352 subjects who used sitagliptin for < 24 weeks. An additional 12-month observation period was monitored after initiating sitagliptin to extract clinical information at 3, 6, 9, and 12 months through patient medical chart review.
  
  
  RESULTS
  In the 2729 continuous users, a baseline glycated hemoglobin (HbA1c) level of 9.0% was reduced to 8.1%, 8.1%, 8.1%, and 8.2% at 3, 6, 9, and 12 months, respectively, representing a 0.9% HbA1c level reduction at 3, 6, and 9 months and a 0.8% HbA1c level reduction at 12 months. With a goal of HbA1c value of < 7.0%, 9.1% of the patients were under control at baseline; after initiating sitagliptin, 22.7% of the patients achieved the HbA1c level goal at 3 months, 23.6% at 6 months, 20.8% at 9 months, and 20.4% at 12 months. The proportion of patients attaining the goal of HbA1c level < 7.0% at least doubled at different time points after treatment with sitagliptin.
  
  
  CONCLUSIONS
  In this single-hospital retrospective chart analysis, a meaningful clinical improvement in glycemic control before and after sitagliptin treatment commenced, including HbA1c level reduction and the HbA1c goal attainment rate, was observed. The results reflect the actual clinical practice in a large hospital in Taiwan, and supplement data from randomized controlled trials.
authors.affiliation: Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
authors.forename: Tse-Ying
authors.initials: TY
authors.lastname: Chen
authors.forename: Ching-Jung
authors.initials: CJ
authors.lastname: Hsieh
mesh_terms: D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D011719:Pyrazines; D000068900:Sitagliptin Phosphate; D014230:Triazoles